Skip to main content

2 Result(s)

within Chuanjian Tu Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes

    Breast cancer subtypes based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression have significant implications for prognosis. HER2-positive tum...

    Wu Ding, Dengfeng Ye, Haifeng Chen, Yingli Lin, Zhian Li, Chuanjian Tu in Breast Cancer (2024)

  2. No Access

    Article

    Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials

    Endocrine therapy with aromatase inhibitors (AIs) is the cornerstone of adjuvant systemic treatment for postmenopausal patients with hormone receptor-positive breast cancer. It has become clear that hormone re...

    **aoying Qian, Zhian Li, GuoDong Ruan, Chuanjian Tu… in Breast Cancer Research and Treatment (2020)